“…Active targeting of NEs can be achieved by surface modification with targeting ligands, such as antibodies (Ansell et al, 2000), aptamers (Wu et al, 2015, Aaldering et al, 2015 and small molecules (Kue et al, 2016) (Milane et al, 2010). Targeting moieties that can be conjugated to NEs to target a specific antigenic site include vitamins, aptamers, sugars, peptides, antibodies and synthetic polymers, (Zeng et al, 2013, Tayeb et al, 2017, Talekar et al, 2012, Mulik et al, 2010. Monoclonal antibodies and their derived fragments are commonly used for active tumour targeting due to their exquisite specificity, high affinity and, in the case of Fab fragments and scFv antibodies, their small size (Ahmad et al, 2012).…”